Publications and communications of Sophie SERVAIS

Bayoudh, F., Giot, J.-B., Descy, J., Fontaine, C., Hayette, M.-P., Baron, F., WILLEMS, E., Beguin, Y., FRIPPIAT, F., & Servais, S. (March 2024). Oral minocycline as systemic therapy for uncomplicated venous access device-related bloodstream infection with coagulase-negative staphylococci after allogeneic hematopoietic cell transplantation. Current Research in Translational Medicine, 72 (1), 103422. doi:10.1016/j.retram.2023.103422

Voisot, A., Triffaux, F., Roland, I., Meex, C., Detrembleur, N., Baron, F., WILLEMS, E., WALTREGNY, D., Beguin, Y., & Servais, S. (22 September 2023). Endovesical instillation of Cidofovir in the treatment of BK polyomavirus hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Current Research in Translational Medicine, 71 (1), 103366. doi:10.1016/j.retram.2022.103366

Ritacco, C., Köse, M. C., Courtois, J., Canti, L., Beguin, C., DUBOIS, S., Vandenhove, B., Servais, S., Caers, J., Beguin, Y., Ehx, G.* , & Baron, F.*. (17 March 2023). Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells. iScience, 26 (3), 106085. doi:10.1016/j.isci.2023.106085

Servais, S., Baron, F., LECHANTEUR, C., Seidel, L., BAUDOUX, E., BRIQUET, A., Selleslag, D., Maertens, J., Poire, X., Schroyens, W., Graux, C., De Becker, A., Zachee, P., Ory, A., Herman, J., Kerre, T., & Beguin, Y. (2023). Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis. Frontiers in Immunology, 14. doi:10.3389/fimmu.2023.1106464

Troisfontaine, F., Denis, C., Servais, S., Lousberg, L., & Jerusalem, G. (December 2022). Les CAR-T cells dans le traitement des tumeurs solides : où en sommes-nous ? Revue Médicale de Liège, 77 (12), 706 - 709.

De Voeght, A., WILLEMS, E., Servais, S., Seidel, L., Pirotte, M., Massion, P., Layios, N., Pereira, M., Misset, B., CANIVET, J.-L., Beguin, Y., & Baron, F. (31 August 2022). Overall Survival Rate in Allogeneic Stem Cell Transplanted Patients Requiring Intensive Care Can Be Predicted by the Prognostic Index for Critically Ill Allogeneic Transplantation Patients (PICAT) and the Sequential Organ Failure Assessment (SOFA) Scores. Cancers, 14 (17), 4266. doi:10.3390/cancers14174266

SERVAIS, S., BEGUIN, Y., & BARON, F. (27 May 2022). Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia. Stem Cells Translational Medicine, 11 (5), 461-477. doi:10.1093/stcltm/szac015

BARZIN, A., Geurten, C., WILLEMS, E., Baron, F., Beguin, Y., & Servais, S. (May 2022). Maladie du greffon contre l’hôte aiguë et chronique après allogreffe de cellules souches hématopoïétiques. Revue Médicale de Liège, 77 (5-6), 345 - 353.

Canti, L., Ariën, K. K., Desombere, I., Humblet-Baron, S., Pannus, P., Heyndrickx, L., HENRY, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., SEIDEL, L., Michiels, J., Willems, B., Goossens, M. E., Beguin, Y., Marchant, A., & Baron, F. (11 April 2022). Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients. Cancer Cell, 40 (4), 335-337. doi:10.1016/j.ccell.2022.02.005

GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211.

Canti, L.* , Humblet-Baron, S.* , Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A., & Baron, F. (2021). Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Journal of hematology & oncology, 14 (1), 174. doi:10.1186/s13045-021-01190-3

Catalano, C., SERVAIS, S., BONVOISIN, C., Couturier, B., Hildebrand, M., Etienne, I., MEURIS, C., Goffard, J.-C., Wissing, M., Goldman, M., & Le Moine, A. (2021). Preemptive Antibody Therapy for Vaccine Breakthrough SARS-CoV-2 Infection in Immunocompromised Patients. Transplantation, 105, 282. doi:10.1097/TP.0000000000003942

Courtois, J., Ritacco, C., DUBOIS, S., Canti, L., Vandenhove, B., SEIDEL, L., Daulne, C., CAERS, J., SERVAIS, S., Beguin, Y., Ehx, G., & BARON, F. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 56, 2672-2681. doi:10.1038/s41409-021-01363-1

Ehx, G.* , Ritacco, C.* , HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505

MAQUET, C., BEGUIN, Y., DE PRIJCK, B., WILLEMS, E., SERVAIS, S., & BONNET, C. (2021). Le lymphome diffus à grandes cellules B : nouveau traitement révolutionnaire par des cellules immunitaires génétiquement modifiées appelées «CAR T cells». Revue Médicale de Liège, 76, 476-481.

Narinx, J., SERVAIS, S., BARON, F., BEGUIN, Y., & WILLEMS, E. (2021). Allogreffes de cellules souches hématopoïétiques : principes généraux et progrès récents. Revue Médicale de Liège, 76, 464-469.

Ritacco, C.* , Ehx, G.* , GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0

Rubio, M., Varlet, P., Allain, V., Ballot, C., Cuffel, A., Deschamps, M., Ferrand, C., FOGUENNE, J., Forcade, E., Huynh, A., Guihot, A., Latouche, J.-B., Lemarie, C., Martinroche, G., Morin, F., Nguyen, S., SCHMIT, K., SERVAIS, S., Simonetta, F., ... Zucman, S. (2021). Suivi immunologique des patients traités par cellules CAR-T pour hémopathie maligne: recommandations du groupe CARTi et de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bulletin du Cancer, 108, 53-S64. doi:10.1016/j.bulcan.2021.04.008

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619

Pirotte, M.* , Forte, F.* , Lutteri, L., WILLEMS, E., DURAN, U., Belle, L., Baron, F., BEGUIN, Y., Maquet, P., BODART, O.* , & Servais, S.*. (2018). Neuronal surface antibody-mediated encephalopathy as manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Journal of Neuroimmunology, 323, 115-118. doi:10.1016/j.jneuroim.2018.08.003

SERVAIS, S., Hannon, M., Peffault de Latour, R., Socie, G., & BEGUIN, Y. (2017). Reconstitution of adaptive immunity after umbilical cord blood transplantation and clinical implication regarding risk of infections. Stem Cell Investigation, 4, 40.

Vrancken, L., Delens, L., BEGUIN, Y., BARON, F., & SERVAIS, S. (2017). Focus sur les lymphocytes T dans la maladie du greffon contre l'hôte après allogreffe de cellules soucges hématopoïétiques: implications pour de nouvelles stratégies de prévention. OncoHemato : Revue Multidisciplinaire d'Oncologie et Hématologie, 11, 23-31.

Glauzy, S., Peffault de Latour, R., André-Schmutz, I., Lachuer, J., SERVAIS, S., SOCIE, G., CLAVE, E., & TOUBERT, A. (September 2016). Alterations of circulating lymphoid committed progenitor cellular metabolism after allogeneic stem cell transplantation in humans. Experimental Hematology, 44 (9), 811-816. doi:10.1016/j.exphem.2016.05.008

SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498

SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235.

HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374

SERVAIS, S., Menten-Dedoyart, C., Beguin, Y., SEIDEL, L., Gothot, A., Daulne, C., WILLEMS, E., Delens, L., Humblet-Baron, S., Hannon, M., & Baron, F. (2015). Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. PLoS ONE, 10 (6), 0130026. doi:10.1371/journal.pone.0130026

Glauzy, S., André-Schmutz, I., Larghero, J., Ezine, S., Peffault de Latour, R., Moins-Teisserenc, H., SERVAIS, S., Robin, M., Socie, G., Clave, E., & Toubert, A. (12 March 2014). CXCR4-related increase of circulating human lymphoid progenitors after allogeneic hematopoietic stem cell transplantation. PLoS ONE, 9 (3), 91492. doi:10.1371/journal.pone.0091492

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9

BEGUIN, Y., Maertens, J., DE PRIJCK, B., Schots, R., Seidel, L., BONNET, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., SERVAIS, S., JASPERS, A., FILLET, G., & BARON, F. (2013). Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation : A prospective multicenter randomized trial. American Journal of Hematology, 88, 990-996. doi:10.1002/ajh.23552

SERVAIS, S., Beguin, Y., & Baron, F. (2013). Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Emerging Drugs, 18 (2), 173-192. doi:10.1517/14728214.2013.798642

SERVAIS, S., WILLEMS, E., Beguin, Y., & Baron, F. (2013). Allogreffe de cellules souches hématopoïétiques chez le patient âgé : jusqu'à quel âge ? Revue Médicale de Liège, 68 (1), 38-43.

Baron, F., & SERVAIS, S. (2012). Rituximab et maladie du greffon contre l'hôte chronique. Horizons Hemato, 2 (2), 78-81.

FRUSCH, N., SERVAIS, S., DE PRIJCK, B., Corhay, J.-L., Beguin, Y., Louis, R., & DUYSINX, B. (2012). Spontaneous pneumomediastinum caused by bleomycin-induced pneumonitis. Acta Clinica Belgica, 67-68. doi:10.2143/ACB.67.5.2062693

Malaise, O., FRUSCH, N., BECK, E., Servais, S., BETEA, D., CAERS, J., DE PRIJCK, B., & BEGUIN, Y. (2012). Panhypopituitarism and diabetus insipidus in a patient with primary central nervous system lymphoma. Leukemia and Lymphoma, 53 (12), 2515-16.

SERVAIS, S., & Baron, F. (2012). Allogreffe de cellules souches hématopoïétiques après conditionnements réduits ("minigreffes") comme traitement de certaines pathologies hématologiques malignes. OncoHemato : Revue Multidisciplinaire d'Oncologie et Hématologie, 6, 6-12.

VERTENOEIL, G., SERVAIS, S., & Beguin, Y. (2012). Comment j'explore... une fièvre d'origine indéterminée chez le patient adulte ? Revue Médicale de Liège, 67 (7-8), 391-397.

SERVAIS, S., Baron, F., & Beguin, Y. (2011). Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning. Transfusion and Apheresis Science, 44, 205-210. doi:10.1016/j.transci.2011.01.019

Servais, S., Beguin, Y., & Baron, F. (2011). Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation (HSCT). Belgian Journal of Hematology, 2, 3-9.

Servais, S., Caers, J., Warling, O., Frusch, N., Baron, F., De Prijck, B., & Beguin, Y. (2010). Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma. British Journal of Haematology, 150 (3), 379-381. doi:10.1111/j.1365-2141.2010.08202.x

Servais, S., Willems, E., Beguin, Y., & Baron, F. (2010). Maladie du greffon contre l'hôte chronique : une prise en charge multidisciplinaire. Revue Médicale de Liège, 65, 81-87.

Servais, S., Ansseau, M., Mikolajczak, G., & Desseilles, M. (2008). L'électroconvulsivothérapie en 2008. Revue Médicale de Liège, 63, 404-410.

JASPERS, A., BARON, F., MAERTENS, J., DE PRIJCK, B., SCHOTS, H., BONNET, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & BEGUIN, Y. (December 2014). Long-term safety follow-up of a rendomized trial of Darbepoetin Alpha and intravenous iron following autologous hematopoietic cell transplantation. Blood, 124 (21), 3948.

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (February 2012). Longitudinal Monitoring of Immune Reconstitution after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): Impact of T-Cell Depletion of the Graft. Biology of Blood and Marrow Transplantation, 18 (2), 274-S275. doi:10.1016/j.bbmt.2011.12.193

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (2011). Longitudinal Monitoring of Immune Reconstitution After Allogeneic Peripheral Blood Stem Cell Transplantation (HSCT): Impact of T Cell Depletion of the Graft. Belgian Journal of Hematology, Abstracts book (Supplement of 26th General Meeting of the Belgian Hematological Society), 31.